Other patents presented effects associated with the increase of BDNF, such as modulation of the HPA axis by altering the levels of important corticotrophins, as adrenocorticotropic hormone (ACTH) and corticotropin-releasing hormone (CRH), and corticosterone (or cortisol), which were mainly associated with reduced depression-like behavior. The gene discussed is CRH; the disease is depressive symptom measurement.